Moderna (MRNA) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moderna’s latest clinical update centers on its trial “Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults.” The study tracks how several mRNA shots perform on safety and immune response across key respiratory threats, which matters for Moderna’s push to build a broad vaccine platform beyond Covid.
The trial tests multiple vaccine candidates delivered by injection. These include mRNA-1273 for Covid-19, mRNA-1010 for flu, mRNA-1345 for RSV, and mRNA-1647 for CMV, plus FLUAD® as an active flu comparator. The goal is to see how Moderna’s mRNA products stack up against an approved flu shot while also mapping immune responses across several diseases.
This is a Phase 1 interventional study with randomized group assignment and a parallel group setup. There is no blinding, and the main aim is prevention, so the focus is on safety and early signs of protection rather than direct disease outcomes, giving investors a look at pipeline breadth more than near-term revenue.
The trial was first submitted on May 25, 2022, marking the formal start of the regulatory record. It is now listed as completed, but the estimated primary and final completion dates are not yet paired with posted results, and the record was last updated on March 10, 2026, signaling fresh data handling or protocol updates.
For investors, the completion of this study is a small but important step in de-risking Moderna’s multi-pathogen vaccine strategy. Positive data could support future combo shots and reinforce the company’s move into flu, RSV, and CMV, where it competes with Pfizer, GSK, and traditional flu players; updates like this tend to support sentiment on the platform even if they do not move the stock on their own.
The study record confirms the program has advanced to completion and was recently updated, with more detailed information available on the ClinicalTrials portal.
To learn more about MRNA’s potential, visit the Moderna drug pipeline page.